Seeking Alpha
 

Acrux Ltd. (ARUXF)

- OTCPK - Current
  • Nov. 24, 2010, 8:26 AM
    The FDA approves Axiron, Eli Lilly's (LLY) topical solution for testosterone replacement therapy in men. The U.S. testosterone market, estimated at $1B, is set to grow 20% annually. Acrux (ARUXF.PK), Lilly's Australian partner on the drug, rose 9.1% in Aussie trading.
    | Comment!
Visit Seeking Alpha's
ARUXF vs. ETF Alternatives
Company Description
Currently, there's no company description for ARUXF.
Sector: Healthcare
Country: Australia